NEO 股利： Neogenomics Inc 收益洞察

Q: Neogenomics Inc 的關鍵財務報表是什麼？

根據最新的財務報表（Form-10K），Neogenomics Inc 的總資產為 $1,638，淨損失為 $-78

Q: NEO 的關鍵財務比率是什麼？

Neogenomics Inc 的流動比率為 2.22，淨利潤率為 -11.81，每股銷售為 $5.21。

Q: Neogenomics Inc 的收入按細分市場或地理位置如何劃分？

Neogenomics Inc 最大收入來源為 Client Direct Billing，在最近的收益報告中收入為 475,444,000。就地區而言，United States 是 Neogenomics Inc 的主要市場，收入為 660,566,000。

Q: Neogenomics Inc 是否盈利？

無，根據最新的財務報表，Neogenomics Inc 的淨損失為 $-78

Q: Neogenomics Inc 有負債嗎？

是的，Neogenomics Inc 的負債為 735

Q: Neogenomics Inc 的流通股有多少？

Neogenomics Inc 的總流通股為 128.14

首頁

股票

NEO

NEO 財務

Neogenomics Inc

$12.79

-0.31%

$-0.04

收盤價：Jan 16, 16:00:00 GMT-5

$12.48

-2.36%

$-0.3

盤後：Jan 16, 20:00:00 GMT-5

概觀預測收益股利財務狀況

關鍵數據

前收市價

$12.83

開盤價

$12.83

當日範圍

$12.48 - $13

52週區間

$4.72 - $15.32

交易量

3.7M

平均成交量

2.4M

每股盈餘 (TTM)

-0.89

股息收益率

市值

$1.6B

什麼是 NEO？

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,200 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

功能特性

交易策略

資源

市場

收入

資產負債表

現金流量

年度

每季

NEO 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
營收	709	660	591	509	484	444
營收年增率 (YoY)	10%	12%	16%	5%	9%	9%
營收成本	400	370	347	321	297	258
毛利	308	290	244	187	187	185
銷售、一般及管理費用	351	310	279	277	229	169
研發	35	29	25	28	21	8
營業費用	400	375	341	341	290	197
其他非營業收入 (費用)	0	0	0	0	0	11
稅前淨利	-113	-80	-97	-159	-15	-14
所得稅費用	0	-1	-9	-15	-6	-18
淨利	-113	-78	-87	-144	-8	4
淨利成長	47%	-10%	-40%	1,700%	-300%	-50%
稀釋後流通股數	128.41	126.65	125.5	124.2	120	111.8
股數年變動 (YoY)	1%	1%	1%	4%	7%	8%
每股盈餘 (稀釋)	-0.88	-0.62	-0.7	-1.16	-0.07	0.04
每股盈餘成長率	44%	-11%	-40%	1,557%	-275%	-50%
自由現金流	-17	-34	-30	-96	-90	-27
每股自由現金流	--	--	--	--	--	--
毛利率	43.44%	43.93%	41.28%	36.73%	38.63%	41.66%
營業利益率	-12.97%	-12.87%	-16.24%	-30.05%	-21.28%	-2.47%
淨利率	-15.93%	-11.81%	-14.72%	-28.29%	-1.65%	0.9%
自由現金流利潤率	-2.39%	-5.15%	-5.07%	-18.86%	-18.59%	-6.08%
EBITDA	-23	-13	-24	-84	-50	24
EBITDA 利潤率	-3.24%	-1.96%	-4.06%	-16.5%	-10.33%	5.4%
EBITDA 中的折舊與攤銷	69	72	72	69	53	35
EBIT	-92	-85	-96	-153	-103	-11
EBIT 利潤率	-12.97%	-12.87%	-16.24%	-30.05%	-21.28%	-2.47%
有效稅率	0%	1.25%	9.27%	9.43%	40%	128.57%

Follow-Up Questions

Neogenomics Inc 的關鍵財務報表是什麼？



NEO 的關鍵財務比率是什麼？



Neogenomics Inc 的收入按細分市場或地理位置如何劃分？



Neogenomics Inc 是否盈利？



Neogenomics Inc 有負債嗎？



Neogenomics Inc 的流通股有多少？



Neogenomics Inc（NEO）價格

NEO 股價走勢圖